ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing
Source: SeekingAlpha
2026-02-27 18:08:26 ET
More on ALX Oncology
- ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
- ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- ALX Oncology jumps on venture capital fund share purchase
- ALX Oncology announces pricing of underwritten offering; shares up nearly 15%
Read the full article on Seeking Alpha
For further details see:
ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing
ALX Oncology Holdings Inc.
NASDAQ: ALXO
ALXO Trading
3.7% G/L:
$2.24 Last:
722,457 Volume:
$2.16 Open:
ALXO Latest News
February 27, 2026 08:00:00 am
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALXO Stock Data
$136,900,453
32,964,545
2.6%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
